Post-earnings recap
Reported
Thu, Mar 9, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss of $0.21 per share, which was below expectations, though the stock rose by 8.66%. This increase may reflect investor optimism or a response to other market factors, despite the lack of revenue and guidance information. The absence of detailed management commentary leaves uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | -105.88% |
| Revenue | $0 | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.